20 May 2013
Keywords: Amgen, Xencor, Autoimmune diseases, XmAb5871, Licensing
Article | 07 January 2011
US biotech major Amgen (Nasdaq: AMGN) and privately-held Xencor have signed a collaboration to develop XmAb n5871, an Fc- engineered ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
7 January 2011
6 January 2011
17 May 2013
© 2013 thepharmaletter.com